Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib for GVHD Prophylaxis in SCT
NCT04961801Phase 2Withdrawn
- Start
- Mar 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of acalabrutinib in graft-versus-host disease (GVHD). Planned start Mar 2022; status: withdrawn.
02
Drugs
acalabrutinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04961801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961801.